Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks
August 21, 2015Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs
Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …
Sun Pharma gets FDA approval for acne treatment
August 21, 2015Medical Communications, Research and Development, Sales and Marketing Sun Pharma. acne treatments, drug approvals
The FDA has approved Sun Pharma’s new acne treatment, Ximino.The Ximino (minocycline hydrochloride) extended-release capsules, which will be available in …
Horizon Pharma receives third rejection from Depomed
August 21, 2015Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …
Monique Levy joins Google’s healthcare advisory board
August 20, 2015Medical Communications google
Monique Levy, vice president of digital innovation at healthcare data and analytics firm Decision Resources Group, is joining Google’s healthcare …
FDA hits Mylan’s Indian plants with warning letter
August 20, 2015Manufacturing and Production Contamination, FDA, Mylan, Pfizer, manufacturing, production
The FDA has served Mylan with a warning letter citing contamination at three of its manufacturing facilities in India. Inspections …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Valeant confirms $1bn deal for ‘female viagra’ creator Sprout
August 20, 2015Manufacturing and Production, Sales and Marketing Addyi, Sprout, Sprout Pharma, Sprout Pharmaceuticals, Valeant, flibanserin
Canada’s Valeant Pharmaceuticals has confirmed it will pay $1 billion to acquire Sprout Pharmaceuticals, the company behind the female libido …
Lundbeck sheds 1,000 jobs in £284 million restructure
August 20, 2015Manufacturing and Production, Sales and Marketing Lundbeck, generics, job losses, patents, redundancies, restructure, restructuring
Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus …
Amgen agrees to $71m settlement over false advertising
August 19, 2015Sales and Marketing Amgen, Aranesp, Enbrel
Amgen has reached a $71 million settlement with 48 US states and the District of Columbia, to resolve allegations that …
FDA approves ‘female viagra’
August 19, 2015Research and Development, Sales and Marketing Addyi, FDA, HSDD, Sprout, Sprout Pharmaceuticals, flibanserin, hypoactive sexual desire disorder
The FDA has approved Sprout Pharmaceuticals’ Addyi, a controversial libido-enhancing drug for women that has been dubbed the ‘female viagra’. …
Nottingham receives go ahead for new £30m life science facility
August 19, 2015Manufacturing and Production, Research and Development BioCity Nottingham, R&D
Hundreds of pharma jobs are expected to be created in Nottingham after the construction of a new £30 million life …
Confronting the ‘danger’ of blocking progress on clinical trial transparency
August 19, 2015Research and Development EMIG, Ethical Medicines Industry Group, Richmond Pharmacology, clinical trial registration, clinical trial transparency, health research authority, hra, sense about science, transparency
The Ethical Medicines Industry Group and Sense About Science – a co-founder of the ALLTrials campaign – have written a …
HRA must continue ‘progress towards clinical trial transparency’
August 19, 2015Research and Development EMIG, Ethical Medicines Industry Group, Richmond Pharmacology, clinical trial registration, clinical trial transparency, health research authority, hra, sense about science, transparency
Campaigners and industry leaders have urged the Health Research Authority to ensure that its work to bring about full transparency …
Kite Pharma says trial death was unrelated to KTE-C19
August 18, 2015Medical Communications, Research and Development CAR-T, cinical trials, kite pharma, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma
Kite has confirmed last week’s rumours that a patient had died during its Phase I/II trial for the KTE-C19 non-Hodgkin’s …
Biogen collaborates with ALSA and Columbia University on genomic-based ALS treatments
August 18, 2015Research and Development
Biogen, the ALS Association and Columbia University Medical Center (CUMC) have announced a new collaboration aimed at better understanding the differences …
Birmingham opens BioHub for life science start-ups
August 18, 2015Manufacturing and Production Birmingham, Diagnostics, hubs, life sciences, research hubs, start-ups
A £7 million biomedical laboratory has opened in Birmingham to attract life-science researchers and start-ups. The BioHub is a new …
New NICE guidelines to tackle antibiotic ‘addiction’
August 18, 2015Manufacturing and Production AMR, Antibiotics, NICE, antimicrobial resistance, guidance, infections
NICE has published guidance to help health care professionals promote and monitor the sensible use of antibiotics – and support …
Roche lung cancer therapy succeeds in mid-stage trial
August 17, 2015Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer
Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
FDA approves limited OxyContin use in children
August 17, 2015Sales and Marketing FDA, OxyContin, Purdue, Purdue Pharma, oxycodone
The FDA has approved the limited use of the strong painkiller Oxycontin for children in the US aged between 11 …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
